109995 ⎘
dsDNA viruses; Details; Poxviridae Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
ENHANCING ONCOLYTIC VIROTHERAPY WITH A COMBINATION OF NUCLEAR EXPORT INHIBITOR AND MYXOMA VIRUS ACTIVATING CELL DEATH PATHWAYS
#2ONCOLYTIC VIRUS EXPRESSING A CAR T CELL TARGET AND USES THEREOF
#3HUMANIZED RECOMBINANT VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN (hrVCP) FOR PROTECTION OF COGNITIVE FUNCTION
#4THERAPEUTIC AGENT COMPRISING MULTISPECIFIC ANTIBODY AND USE THEREOF IN TUMOR THERAPY
#5CANCER THERAPIES COMPRISING A NUCLEAR EXPORT INHIBITOR AND AN ONCOLYTIC VIRUS
#6RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS
#7COMPOSITION AND METHODS INCLUDING RECOMBINANT VIRUSES MODULATING ARGININE BIOSYNTHESIS
#8ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS
#9Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
#10ONCOLYTIC MYXOMA VIRUS EXPRESSING FAST P14 TO TREAT HEMATOLOGICAL CANCER
#11ONCOLYTIC VIRUS PLATFORM TO TREAT HEMATOLOGICAL CANCER
#12Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
#13ONCOLYTIC VIRUS EXPRESSING A CAR T CELL TARGET AND USES THEREOF
#14COMPOSITION FOR TREATING CANCEROUS CELLS AND A METHOD THEREFOR
#15Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
#16Anti-cancer oncolytic virus combination therapies and elite responder selection platforms
#17USE OF A COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT
#18Composition for treating cancerous cells and a method therefor
#19Myxoma virus mutants for cancer treatment
#20Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
#21Attenuated strain of myxoma virus for use as an oncolytic drug
#22MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES
#23MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES
#24MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES
#25USE OF A COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT
#26Myxoma virus mutants for cancer treatment
#27Monoparamunity inducers based on attenuated rabbit myxoma viruses
#28Methods of preparing myxomavirus compositions
#29Monoparamunity inducers based on attenuated rabbit myxomaviruses
#30Use of Myxoma virus for the therapeutic treatment of cancer and chronic viral infection
#31USE OF A COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT
#32Monoparamunity inducers based on attenuated rabbit myxomaviruses
#33Monoparamunity inducers based on attenuated rabbit myxomaviruses
#34Poxvirus Vector Encoding Prostate Specific Antigens For Treatment Of Prostate Cancer
#35Paramunity inducers based on attenuated rabbit myxoma virus
#36Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
#37Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC